{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-342667","form_type":"8-K","ticker":"JAZZ","cik":"0001232524","company_name":"Jazz Pharmaceuticals plc","filed_at":"2026-08-10T21:13:18+00:00","discovered_at":"2026-08-10T21:14:12.234464+00:00","generated_at":"2026-08-10T21:14:29.221553+00:00","sec_items":["1.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Jazz to acquire Actio Biosciences for $820M upfront plus up to $500M in milestones","bullets":["Upfront consideration of $820M; contingent milestones up to $500M (ABS-1230 regulatory approval and sales thresholds).","Milestones: $250M on regulatory approval for ABS-1230 in KCNT1-Related Epilepsy; $100M at $500M annual sales; $150M at $1B annual sales.","Spin-Out: non-ABS-1230 programs transferred to SpinCo; Jazz retains minority equity stake.","Closing conditions: HSR clearance, 85% stockholder approval, Spin-Out completion, no termination fees."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-342667","json":"https://secwatch.observer/filing/0001193125-26-342667.json","markdown":"https://secwatch.observer/filing/0001193125-26-342667.md","text":"https://secwatch.observer/filing/0001193125-26-342667.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1232524/000119312526342667/0001193125-26-342667-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1232524/000119312526342667/d151973d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-10T21:14:29.221553+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}